Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational study

Journal of the National Cancer Institute

Volumn 105, Issue 8, 2013, Pages 526-535

  Chlebowski, Rowan T ^a   Manson, Joann E ^b   Anderson, Garnet L ^c   Cauley, Jane A ^d   Aragaki, Aaron K ^c   Stefanick, Marcia L ^e   Lane, Dorothy S ^f   Johnson, Karen C ^g   Wactawski Wende, Jean ^h   Chen, Chu ^c   Qi, Lihong ⁱ   Yasmeen, Shagufta ⁱ   Newcomb, Polly A ^c   Prentice, Ross L ^c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e STANFORD UNIVERSITY   (United States)

^f STONY BROOK UNIVERSITY   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h UNIVERSITY AT BUFFALO   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; PROGNOSIS; SEER PROGRAM; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; WOMEN'S HEALTH;

EID: 84876551405     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt043     Document Type: Article

References (38)

1. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289(24):3243-3253. (Pubitemid 37430077)
2. Chlebowski RT, Anderson GL. Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst. 2012;104(7):1-11.
3. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684-1692.
4. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332(24):1589-1593.
5. Bergkvist L, Adami HO, Persson J, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol. 1989;130(2):221-228. (Pubitemid 19204291)
6. Antoine C, Liebens F, Carly B, et al. Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Human Reprod. 2004;19(3):741-756. (Pubitemid 38344544)
7. Chen W, Petitti DB, Geiger AM. Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study. Br J Cancer. 2005;93(4):392-398. (Pubitemid 43080011)
8. Newcomb PA, Egan KM, Trentham Dietz A, et al. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(4):864-871. (Pubitemid 351536417)
9. Norman SA, Weber AL, Localio AR, et al. Hormone therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf. 2010;19(5):440-447.
10. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol. 2008;167(10):1207-1216. (Pubitemid 351670642)
11. Chlebowski RT, Anderson GL. The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. J Natl Cancer Inst. 2011;103(4):284-285.
12. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Am Epidemiol. 2003;13(9):S5-S17. (Pubitemid 37324175)
13. McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women. JAMA. 2003;290(10):1331-1336.
14. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/. Accessed May 22, 2012.
15. Gail MH. Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med. 2011;30(10):1090-1104.
16. Chlebowski RT, Anderson GL, Pettinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med. 2008;168(4):370-377. (Pubitemid 351347128)
17. Joffe MM, Byrne C, Colditz GA. Postmenopausal hormone use, screening and breast cancer characterization and control of a bias. Epidemiology. 2001;12(4):429-438. (Pubitemid 32566485)
18. Hofvind S, Sorum R, Haldorsen T, Langmark F. Incidence of breast cancer before and after implementation of mammography screening. Tidsskr Nor Laegeforen. 2006;126(22):2935-2938. (Pubitemid 44801379)
19. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol. 2003;21(23):4314-4321. (Pubitemid 46621806)
20. Sihto H, Lundin J, Lehtimaki T, et al. Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res. 2008;14(13):4103-4110.
21. Dong W, Berry DA, Bevers TB, et al. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the University of Texas MD Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev. 2008;17(5):1096-1103.
22. Gordon NP, Hiatt RA, Lampert DI. Correspondence of self-reported data and medical record audit for six cancer screening procedures. J Natl Cancer Inst. 1993;85(7):566-570. (Pubitemid 23110931)
23. Weiss NS. Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. Am J Epidemiol. 2003;157(11):957-961. (Pubitemid 36628796)
24. Christante D, Pommier S, Garreau J, et al. Improved breast cancer survival among hormone replacement therapy user is durable after 5 years of additional follow-up. Am J Surg. 2008;196(4):505-511.
25. Rosenberg LU, Granath F, Dickman PW, et al. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res. 2008;10(5):R78.
26. Reding KW, Doody DR, McTiernan A, et al. Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer. Breast Cancer Res Treat. 2001;126(3):749-761.
27. Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogenprogestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol. 2009;27(31):5138-5143.
28. Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103(4):296-305.
29. James RE, Lukanova A, Dossus L, et al. Postmenopausal serum sex steroids and risk of hormone receptor-positive and negative breast cancer: a nested case-control study. Cancer Prev Res (Phila). 2011;4(10):1626-1635.
30. Ritte RE, Lukanova A, Berrino F, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res. 2012;14:R76.
31. Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancer. Cell Biology & Therapy 2010;10 (10):955-960.
32. North American Menopause Society. The 2012 hormone position statement of the North American Menopause Society. Menopause. 2012;19(3): 257-271.
33. Gompel A, Rozenberg S, Barlow DH. The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas. 2008;61(3):227-232.
34. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389-1399.
35. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause. 2011;18(4): 385-392.
36. Pollan M, Pastor-Barriuso R, Ardanaz E, et al. Recent changes in breast cancer incidence in Spain, 1980-2004. J Natl Cancer Inst. 2009;101(22):1584- 1591.
37. Lacroix AZ, Chlebowski RT, Manson JE, et al. Health risks and benefits 5 years after stopping randomized treatment with conjugated equine estrogens in postmenopausal women with prior hysterectomy. JAMA. 2011;305(13):1305-1314.
38. Anderson GL, Chlebowski RT, Aragaki A, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomized placbeo-controlled trial. Lancet Oncol. 2012;13(5):476-486.